A recent study by Ren et al.1 contributes to the ongoing debate about how interactions between factions of the Bcl-2 protein family provoke apoptosis, but the data presented do not, in our view, support the overall conclusion that ‘Bid, Bim and Puma are essential for activation of the Bax- and Bak-dependent cell death program'.
It is generally accepted that, in response to diverse cellular stresses, the Bcl-2 distant cousins termed ‘BH3-only proteins', for example, Bim, Bid or Puma, initiate the apoptotic process and that the pivotal step (mitochondrial outer membrane permeabilization) requires the proapoptotic Bcl-2 family members Bak or Bax,2 but how the BH3-only proteins provoke activation of Bax and Bak remains controversial. The ‘direct activation' model3 posits that Bim, Bid and possibly Puma serve as direct ‘activators'. In healthy cells, prosurvival Bcl-2 proteins sequester them, but cytotoxic stimuli upregulate or activate ‘sensitizer BH3-only proteins' (Bad, Bik, Hrk, Noxa and Bmf) whose binding to the prosurvival Bcl-2 proteins liberates the ‘activators' to transiently engage and activate Bax/Bak. Conversely, the ‘indirect model'4 postulates that in healthy cells a small proportion of Bax and Bak is primed to elicit cell death but sequestered by prosurvival Bcl-2 proteins, and that BH3-only proteins must engage all prosurvival proteins in a given cell to unleash Bax/Bak for death duty. This can either be achieved by Bim, Puma or Bid, which can bind all their prosurvival relatives, or by combinations of BH3-only proteins that bind complementary subsets (e.g., Bad, binding Bcl-2, Bcl-xL and Bcl-w, plus Noxa, binding Mcl-1 and A14, 5). Although biochemical studies have provided conflicting results, the indirect activation model was supported by the observation that Bax/Bak double-deficient (DKO) mice2 have much more severe developmental and apoptotic defects than mice lacking Bim and Bid,4 the two most widely accepted ‘direct activators' within the Bcl-2 family.
Ren et al.1 generated Bim/Bid/Puma triple-deficient (TKO) mice to resolve whether Puma also functions as a ‘direct activator' and to clarify the mechanisms of Bax/Bak activation. They report that triple deficiency for Bim, Bid and Puma mirrors Bax/Bak double deficiency and argue that this provides proof for the ‘direct activation' model. This is, however, incorrect. First, there are substantial differences in phenotype between Bim/Bid/Puma TKO1 and Bax/Bak DKO mice.2 Although Bax/Bak DKO mice die perinatally with severe brain abnormalities, no such profound neurological defects and associated perinatal lethality were reported for the Bim/Bid/Puma TKO mice. Furthermore, although some interdigital webbing persisted in Bim/Bid/Puma TKO mice,1 it appears less extensive than in Bax/Bak DKO mice2 or in Bim−/−Bmf−/− mice6 (AV, PB and VL, unpublished), in which webs persist despite the presence of both Bid and Puma. Moreover, the defect in vaginal development in Bim/Bid/Puma TKO mice shows incomplete penetrance,1 but occurs in 100% of Bax/Bak DKO mice.2 Thus, in a significant portion of Bim/Bid/Puma TKO mice, the physiological cell death driven by Bax and/or Bak continues to some extent in multiple tissues.
The reported in vitro cell survival assays also fail to unambiguously demonstrate that all induction of apoptosis requires Bid, Bim or Puma. A proportion of the TKO lymphoid cells still died in response to DNA damage or glucocorticoids,1 whereas Bax/Bak DKO cells are fully refractory.2 This difference may indicate that these death stimuli activate additional (i.e., non ‘direct activator') BH3-only proteins that collectively can neutralize the prosurvival Bcl-2 proteins in these cells, thereby leading to Bax/Bak activation, consistent with the ‘indirect model'. Moreover, the role of Bid in the lymphocyte death probably is negligible: although this study failed to provide data on survival of Bim/Puma DKO lymphocytes, previous studies7, 8 have shown that their combined loss renders multiple hematopoietic cell types as resistant to the apoptotic stimuli studied as reported for the Bim/Bid/Puma TKO cells.1
Thus, the phenotype of the TKO mice is less profound than that of Bax/Bak DKO animals and does not prove the direct activation model. As the TKO mice lack the three BH3-only proteins that can neutralize all the prosurvival family members,5 the observed apoptotic deficiencies are also compatible with the ‘indirect model'. Nevertheless, increasing in vitro findings, for example,9, 10 suggest that certain BH3 domains can directly activate Bax, and a recent in vivo study using gene-targeted mice in which the BH3 region of Bim has been subtly altered argues that aspects of both models may well hold.11 Most of the seemingly conflicting published results can be reconciled if Bax and Bak can be activated in multiple ways: in some circumstances by Bid, Bim or Puma, but also, albeit perhaps less efficiently, by certain other BH3-only proteins,12 or by mechanisms independent of BH3-only proteins,3 such as by Bax phosphorylation, heat-induced conformational change, or spontaneous activation after the neutralization or degradation of the restraining prosurvival Bcl-2 proteins, as seen in platelets. As small molecules that target prosurvival Bcl-2 proteins are showing great clinical promise, it will be essential to understand these mechanisms to achieve optimal killing of tumor cells.
References
- Ren D, et al. Science (New York, NY) 2010. p. 1390. [DOI] [PMC free article] [PubMed]
- Lindsten T, et al. Mol Cell. 2000. p. 1389. [DOI] [PMC free article] [PubMed]
- Chipuk JE, Green DR. Trends Cell Biol. 2008. p. 157. [DOI] [PMC free article] [PubMed]
- Willis SN, et al. Science (New York, NY. 2007. p. 856.
- Chen L, et al. Mol Cell. 2005. p. 393. [DOI] [PubMed]
- Hubner A, et al. Mol Cell Biol. 2010. p. 98. [DOI] [PMC free article] [PubMed]
- Erlacher M, et al. J Exp Med. 2006. p. 2939. [DOI] [PMC free article] [PubMed]
- Karlberg M, et al. Cell Death Dis. 2010. p. e43. [DOI] [PMC free article] [PubMed]
- Gavathiotis E, et al. Nature. 2008. p. 1076. [DOI] [PMC free article] [PubMed]
- Lovell JF, et al. Cell. 2008. p. 1074. [DOI] [PubMed]
- Merino D, et al. J Cell Biol. 2009. p. 355. [DOI] [PMC free article] [PubMed]
- Du H, et al. J Biol Chem. 2010. pp. 491–501. [DOI] [PMC free article] [PubMed]